Menu Search
Equities

Genedrive PLC

GDR:LSE

Genedrive PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)2.23
  • Today's Change-0.150 / -6.32%
  • Shares traded3.43m
  • 1 Year change-65.77%
  • Beta-0.6836
Data delayed at least 20 minutes, as of Nov 08 2024 17:12 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in GBPIncome statement in GBPView more

Year on year Genedrive PLC had net income fall 10.16% from a loss of 4.68m to a larger loss of 5.15m despite a 12.24% increase in revenues from 49.00k to 55.00k.
Gross margin--
Net profit margin-1,837.50%
Operating margin-1,802.57%
Return on assets-120.84%
Return on equity-201.53%
Return on investment-197.86%
More ▼

Cash flow in GBPView more

In 2023, cash reserves at Genedrive PLC fell by 1.99m. Cash Flow from Financing totalled 1.82m or 3,316.36% of revenues. In addition the company used 3.81m for operations while cash used for investing totalled 8.00k.
Cash flow per share-0.0384
Price/Cash flow per share--
Book value per share0.0098
Tangible book value per share0.0098
More ▼

Balance sheet in GBPView more

Genedrive PLC appears to have a strong balance sheet with enough cash in the capital structure to pay down 100% of the liabilities.
Current ratio1.63
Quick ratio1.36
Total debt/total equity0.0857
Total debt/total capital0.0789
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.